Alkermes PLC Stock Price, News & Analysis (NASDAQ:ALKS)

$49.36 1.59 (3.33 %)
(As of 11/22/2017 07:56 AM ET)
Previous Close$47.77
Today's Range$49.58 - $47.73
52-Week Range$46.42 - $63.40
Volume908,015 shs
Average Volume831,235 shs
Market Capitalization$7.35 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.13

About Alkermes PLC (NASDAQ:ALKS)

Alkermes PLC logoAlkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Sector: Medical
  • Symbol: NASDAQ:ALKS
  • CUSIP: G0176710
  • Web: www.alkermes.com
Debt:
  • Debt-to-Equity Ratio: 0.23%
  • Current Ratio: 3.05%
  • Quick Ratio: 2.72%
Sales & Book Value:
  • Annual Sales: $745.69 million
  • Price / Sales: 10.18
  • Book Value: $7.72 per share
  • Price / Book: 6.39
Profitability:
  • Trailing EPS: ($1.11)
  • Net Income: $-208,440,000.00
  • Net Margins: -20.12%
  • Return on Equity: -7.27%
  • Return on Assets: -5.05%
Misc:
  • Employees: 1,750
  • Outstanding Shares: 153,780,000
 

Frequently Asked Questions for Alkermes PLC (NASDAQ:ALKS)

What is Alkermes PLC's stock symbol?

Alkermes PLC trades on the NASDAQ under the ticker symbol "ALKS."

How were Alkermes PLC's earnings last quarter?

Alkermes PLC (NASDAQ:ALKS) issued its quarterly earnings data on Thursday, October, 26th. The company reported $0.03 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.01) by $0.04. The business earned $217.40 million during the quarter, compared to analyst estimates of $231.29 million. Alkermes PLC had a negative net margin of 20.12% and a negative return on equity of 7.27%. The company's revenue for the quarter was up 20.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.09) EPS. View Alkermes PLC's Earnings History.

When will Alkermes PLC make its next earnings announcement?

Alkermes PLC is scheduled to release their next quarterly earnings announcement on Tuesday, February, 13th 2018. View Earnings Estimates for Alkermes PLC.

What guidance has Alkermes PLC issued on next quarter's earnings?

Alkermes PLC issued an update on its FY17 earnings guidance on Thursday, October, 26th. The company provided earnings per share guidance of ($0.10) - $0.10 for the period, compared to the Thomson Reuters consensus EPS estimate of ($0.04). The company issued revenue guidance of $850-880 million, compared to the consensus revenue estimate of $893.66 million.

Where is Alkermes PLC's stock going? Where will Alkermes PLC's stock price be in 2017?

10 equities research analysts have issued 1 year price objectives for Alkermes PLC's shares. Their forecasts range from $50.00 to $81.00. On average, they anticipate Alkermes PLC's stock price to reach $64.50 in the next twelve months. View Analyst Ratings for Alkermes PLC.

What are Wall Street analysts saying about Alkermes PLC stock?

Here are some recent quotes from research analysts about Alkermes PLC stock:

  • 1. According to Zacks Investment Research, "Alkermes posted narrower-than-expected loss in the second quarter of 2017 while sales marginally surpassed estimates. Vivitrol and Aristada are anticipated to be primary growth drivers. While, Vivitrol should benefit from the newly passed legislation, CARA, securing reimbursement and access for Aristada also bodes well. The company also plans to submit a new drug application (NDA) for ALKS 5461 in major depressive disorder and expects to complete the pivotal efficacy of ALKS3831 in schizophrenia. However, Alkermes is highly dependent on manufacturing and/or royalty revenues on sales of products that are commercialized by the company’s partners. Given its history of pipeline setbacks, any obstacle in the process of development of the candidates could weigh heavily on the stock. Stiff competition and dependence on partners remains a threat. Moreover, Alkermes’ shares have underperformed the Zacks classified industry year to date." (8/2/2017)
  • 2. Cowen and Company analysts commented, "ALKS reported Q1:17 results which came in below expectations." (4/28/2017)
  • 3. Cantor Fitzgerald analysts commented, "We remain cautious on ALKS stock because we believe it reasonable that the company may not be able to file for regulatory approval of ALKS 5461 (for treating major depressive disorder, MDD) with data from only one positive Phase 3 trial from the three studies that comprise the FORWARD clinical program. We also remain unconvinced that the company will successfully transition from a developer of drug formulation technologies (historically applied to partner's assets) to a developer of proprietary products. As noted in a report we recently published on the evolving multiple sclerosis (MS) landscape, we believe new market entrants could challenge existing drug franchises, in particular that of Biogen (BIIB, Neutral, $277). Even if ALKS 8700 does not reduce GI side effects relative to that experienced with Tecfidera, we believe ALKS would likely seek approval anyway given the hegemony BIIB enjoys in the MS fumarate drug market." (3/16/2017)

Who are some of Alkermes PLC's key competitors?

Who are Alkermes PLC's key executives?

Alkermes PLC's management team includes the folowing people:

  • Richard F. Pops, Chairman, President, and CEO
  • James M. (Jim) Frates, SVP, CFO, and Treasurer
  • Gordon G. Pugh, SVP, COO, and Chief Risk Officer
  • Richard F. Pops, Chairman of the Board, Chief Executive Officer (Age 55)
  • Shane M. Cooke, President (Age 54)
  • James M. Frates, Chief Financial Officer, Senior Vice President, Treasurer (Age 49)
  • Kathryn L. Biberstein, Executive Vice President, Chief Administrative Officer, Chief Compliance Officer, Chief Risk Officer, Secretary (Age 58)
  • Elliot W. Ehrich M.D., Executive Vice President - Research and Development and Chief Medical Officer (Age 57)
  • Iain M. Brown, Senior Vice President - Finance, Chief Accounting Officer (Age 48)
  • David Joseph Gaffin, Senior Vice President, Chief Legal Officer (Age 45)

Who owns Alkermes PLC stock?

Alkermes PLC's stock is owned by a number of of institutional and retail investors. Top institutional investors include Woodford Investment Management Ltd (4.77%), Thornburg Investment Management Inc. (1.81%), Janus Henderson Group PLC (1.72%), Bank of New York Mellon Corp (0.90%), Frontier Capital Management Co. LLC (0.51%) and First Trust Advisors LP (0.44%). Company insiders that own Alkermes PLC stock include David Joseph Gaffin, David W Anstice, Elliot Ehrich, Gordon G Pugh, Iain Michael Brown, James M Frates, Kathryn L Biberstein, Mark Stejbach, Michael J Landine, Paul J Mitchell, Richard F Pops, Robert A Breyer and Shane Cooke. View Institutional Ownership Trends for Alkermes PLC.

Who sold Alkermes PLC stock? Who is selling Alkermes PLC stock?

Alkermes PLC's stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Woodford Investment Management Ltd, First Trust Advisors LP, Frontier Capital Management Co. LLC, State of Wisconsin Investment Board, Canada Pension Plan Investment Board, Granahan Investment Management Inc. MA and California State Teachers Retirement System. Company insiders that have sold Alkermes PLC company stock in the last year include David Joseph Gaffin, Elliot Ehrich, Gordon G Pugh, James M Frates, Kathryn L Biberstein, Mark Stejbach, Michael J Landine, Paul J Mitchell, Richard F Pops, Robert A Breyer and Shane Cooke. View Insider Buying and Selling for Alkermes PLC.

Who bought Alkermes PLC stock? Who is buying Alkermes PLC stock?

Alkermes PLC's stock was bought by a variety of institutional investors in the last quarter, including Thornburg Investment Management Inc., Janus Henderson Group PLC, Asset Management One Co. Ltd., Los Angeles Capital Management & Equity Research Inc., WINTON GROUP Ltd, Russell Investments Group Ltd., Ameriprise Financial Inc. and Sei Investments Co.. View Insider Buying and Selling for Alkermes PLC.

How do I buy Alkermes PLC stock?

Shares of Alkermes PLC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alkermes PLC's stock price today?

One share of Alkermes PLC stock can currently be purchased for approximately $49.36.

How big of a company is Alkermes PLC?

Alkermes PLC has a market capitalization of $7.35 billion and generates $745.69 million in revenue each year. The company earns $-208,440,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis. Alkermes PLC employs 1,750 workers across the globe.

How can I contact Alkermes PLC?

Alkermes PLC's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]


MarketBeat Community Rating for Alkermes PLC (NASDAQ ALKS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  326 (Vote Outperform)
Underperform Votes:  258 (Vote Underperform)
Total Votes:  584
MarketBeat's community ratings are surveys of what our community members think about Alkermes PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Alkermes PLC (NASDAQ:ALKS)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 5 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $64.50 (30.67% upside)

Consensus Price Target History for Alkermes PLC (NASDAQ:ALKS)

Price Target History for Alkermes PLC (NASDAQ:ALKS)

Analysts' Ratings History for Alkermes PLC (NASDAQ:ALKS)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/27/2017J P Morgan Chase & CoSet Price TargetBuy$78.00N/AView Rating Details
10/27/2017Credit Suisse GroupLower Price TargetOutperform$70.00 -> $66.00N/AView Rating Details
10/26/2017Barclays PLCSet Price TargetHold$50.00N/AView Rating Details
10/26/2017Citigroup Inc.Set Price TargetHold$62.00N/AView Rating Details
10/21/2017MizuhoSet Price TargetBuy$81.00N/AView Rating Details
8/25/2017Jefferies Group LLCSet Price TargetBuy$69.00LowView Rating Details
6/13/2017Leerink SwannDowngradeOutperform -> Market Perform$68.00 -> $61.00MediumView Rating Details
4/28/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
4/24/2017Morgan StanleyReiterated RatingEqual Weight$62.00LowView Rating Details
3/16/2017Cantor FitzgeraldReiterated RatingNeutral$51.00MediumView Rating Details
5/26/2016Evercore ISIInitiated CoverageBuy$59.00N/AView Rating Details
2/22/2016Goldman Sachs Group, Inc. (The)Lower Price Target$57.00 -> $35.00N/AView Rating Details
1/21/2016GuggenheimReiterated RatingHoldN/AView Rating Details
(Data available from 11/22/2015 forward)

Earnings

Earnings History and Estimates Chart for Alkermes PLC (NASDAQ:ALKS)

Earnings by Quarter for Alkermes PLC (NASDAQ:ALKS)

Earnings History by Quarter for Alkermes PLC (NASDAQ ALKS)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/13/2018$0.13N/AView Earnings Details
10/26/20179/30/2017($0.01)$0.03$231.29 million$217.40 millionViewN/AView Earnings Details
7/27/20176/30/2017($0.01)$0.01$216.54 million$218.80 millionViewN/AView Earnings Details
4/27/20173/31/2017($0.24)($0.31)$195.79 million$191.80 millionViewN/AView Earnings Details
2/15/2017Q416$0.04$0.15$206.38 million$213.50 millionViewListenView Earnings Details
11/2/2016Q316($0.06)($0.09)$186.39 million$180.20 millionViewListenView Earnings Details
7/28/2016Q216($0.10)($0.01)$174.15 million$195.20 millionViewListenView Earnings Details
4/28/2016Q116($0.20)($0.16)$153.64 million$156.80 millionViewListenView Earnings Details
2/25/2016Q415($0.18)($0.15)$161.24 million$163.10 millionViewListenView Earnings Details
10/29/2015Q315($0.21)($0.18)$151.77 million$152.70 millionViewListenView Earnings Details
7/30/2015Q215($0.10)($0.09)$142.80 million$151.40 millionViewListenView Earnings Details
4/30/2015Q115($0.03)$0.06$146.60 million$161.20 millionViewListenView Earnings Details
2/24/2015Q414$0.04$0.11$161.70 million$175.20 millionViewListenView Earnings Details
10/29/2014Q314($0.12)($0.13)$155.53 million$160.00 millionViewListenView Earnings Details
7/31/2014Q314$0.04($0.01)$146.91 million$153.40 millionViewListenView Earnings Details
4/30/2014Q1$0.10$0.11$135.79 million$130.21 millionViewListenView Earnings Details
2/27/2014Q114$0.20$0.27$142.93 million$154.50 millionViewListenView Earnings Details
10/31/2013$0.22$0.22$137.35 million$139.80 millionViewListenView Earnings Details
7/25/2013Q1 2014$0.22$0.30$131.50 million$138.60 millionViewListenView Earnings Details
5/23/2013Q4 2013$0.17$0.40$128.01 million$163.40 millionViewListenView Earnings Details
1/31/2013Q3 2013$0.23$0.34$130.81 million$135.90 millionViewListenView Earnings Details
11/1/2012Q213$0.11$0.17$121.62 million$124.00 millionViewN/AView Earnings Details
7/26/2012$0.16$0.39ViewN/AView Earnings Details
5/17/2012($0.16)($0.14)ViewN/AView Earnings Details
2/2/2012($0.21)($0.11)ViewN/AView Earnings Details
11/3/2011($0.10)($0.22)ViewN/AView Earnings Details
8/1/2011($0.11)$0.02ViewN/AView Earnings Details
5/18/2011($0.14)($0.14)ViewN/AView Earnings Details
2/3/2011($0.15)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alkermes PLC (NASDAQ:ALKS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.16)($0.16)($0.16)
Q3 20171($0.15)($0.15)($0.15)
Q4 20172($0.10)($0.05)($0.08)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Alkermes PLC (NASDAQ:ALKS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Alkermes PLC (NASDAQ ALKS)

Insider Ownership Percentage: 5.34%
Institutional Ownership Percentage: 99.02%
Insider Trades by Quarter for Alkermes PLC (NASDAQ:ALKS)
Institutional Ownership by Quarter for Alkermes PLC (NASDAQ:ALKS)

Insider Trades by Quarter for Alkermes PLC (NASDAQ ALKS)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/8/2017James M. FratesSVPSell20,932$47.58$995,944.56View SEC Filing  
11/2/2017Richard F PopsDirectorSell50,000$48.87$2,443,500.00View SEC Filing  
11/1/2017Michael J LandineSVPSell15,000$48.71$730,650.00View SEC Filing  
10/2/2017Paul J MitchellDirectorSell1,500$50.64$75,960.00View SEC Filing  
9/11/2017Kathryn L BibersteinCAOSell13,566$51.29$695,800.14View SEC Filing  
9/1/2017Paul J MitchellDirectorSell1,500$50.77$76,155.00View SEC Filing  
8/1/2017Paul J MitchellDirectorSell1,500$54.91$82,365.00View SEC Filing  
7/3/2017Paul J MitchellDirectorSell1,500$58.11$87,165.00View SEC Filing  
6/8/2017Shane CookeInsiderSell10,000$60.33$603,300.00View SEC Filing  
6/1/2017Paul J MitchellDirectorSell1,500$57.49$86,235.00View SEC Filing  
5/24/2017Richard F PopsDirectorSell25,000$57.42$1,435,500.00View SEC Filing  
5/18/2017Michael J LandineSVPSell10,000$57.23$572,300.00View SEC Filing  
5/17/2017Richard F PopsDirectorSell50,000$58.19$2,909,500.00View SEC Filing  
5/11/2017Michael J LandineSVPSell10,000$57.01$570,100.00View SEC Filing  
5/10/2017Richard F PopsDirectorSell25,000$57.29$1,432,250.00View SEC Filing  
5/4/2017Shane CookeInsiderSell6,500$60.05$390,325.00View SEC Filing  
4/17/2017Elliot EhrichCMOSell10,000$56.60$566,000.00View SEC Filing  
4/3/2017Kathryn L BibersteinCAOSell15,000$57.68$865,200.00View SEC Filing  
4/3/2017Paul J MitchellDirectorSell1,500$58.31$87,465.00View SEC Filing  
3/29/2017Shane CookeInsiderSell2,070$60.00$124,200.00View SEC Filing  
3/23/2017Shane CookeInsiderSell6,030$60.01$361,860.30View SEC Filing  
3/21/2017Shane CookeInsiderSell1,900$60.09$114,171.00View SEC Filing  
3/20/2017Shane CookeInsiderSell300$60.00$18,000.00View SEC Filing  
3/15/2017Elliot EhrichCMOSell11,000$56.74$624,140.00View SEC Filing  
3/7/2017James M FratesSVPSell25,000$59.08$1,477,000.00View SEC Filing  
3/2/2017Robert A BreyerDirectorSell4,000$60.00$240,000.00View SEC Filing  
3/2/2017Shane CookeInsiderSell20,000$60.00$1,200,000.00View SEC Filing  
3/1/2017Paul J MitchellDirectorSell1,500$57.06$85,590.00View SEC Filing  
2/16/2017Elliot EhrichCMOSell11,000$56.68$623,480.00View SEC Filing  
2/1/2017Paul J MitchellDirectorSell1,500$54.45$81,675.00View SEC Filing  
1/17/2017Elliot EhrichCMOSell11,983$54.32$650,916.56View SEC Filing  
1/9/2017Mark StejbachSVPSell547$60.27$32,967.69View SEC Filing  
1/9/2017Shane CookeInsiderSell550$60.27$33,148.50View SEC Filing  
1/6/2017Elliot EhrichCMOSell10,000$59.44$594,400.00View SEC Filing  
1/6/2017Mark StejbachSVPSell9,453$60.05$567,652.65View SEC Filing  
1/6/2017Shane CookeInsiderSell9,450$60.06$567,567.00View SEC Filing  
1/4/2017Robert A BreyerDirectorSell4,000$60.00$240,000.00View SEC Filing  
1/3/2017David Joseph GaffinSVPSell2,500$55.40$138,500.00View SEC Filing  
1/3/2017Paul J MitchellDirectorSell1,500$55.40$83,100.00View SEC Filing  
12/16/2016Gordon G PughCOOSell21,458$57.65$1,237,053.70View SEC Filing  
12/15/2016Elliot EhrichCMOSell5,000$55.99$279,950.00View SEC Filing  
12/14/2016James M FratesSVPSell25,000$54.73$1,368,250.00View SEC Filing  
12/12/2016Elliot EhrichCMOSell16,983$55.15$936,612.45View SEC Filing  
12/8/2016Kathryn L BibersteinCAOSell14,145$56.13$793,958.85View SEC Filing  
12/7/2016James M. FratesSVPSell23,731$56.28$1,335,580.68View SEC Filing  
12/1/2016Kathryn L BibersteinCAOSell15,000$56.13$841,950.00View SEC Filing  
11/30/2016Michael J LandineSVPSell10,000$57.51$575,100.00View SEC Filing  
11/29/2016Richard F PopsDirectorSell30,000$56.98$1,709,400.00View SEC Filing  
11/22/2016Richard F PopsDirectorSell30,000$58.66$1,759,800.00View SEC Filing  
10/4/2016Paul J MitchellDirectorSell2,000$47.42$94,840.00View SEC Filing  
9/22/2016Elliot EhrichCMOSell5,000$50.83$254,150.00View SEC Filing  
9/16/2016Elliot EhrichCMOSell5,000$48.87$244,350.00View SEC Filing  
9/6/2016David Joseph GaffinSVPSell2,382$45.92$109,381.44View SEC Filing  
9/6/2016Elliot EhrichCMOSell10,000$46.02$460,200.00View SEC Filing  
9/6/2016Iain Michael BrownCAOSell29,976$45.92$1,376,497.92View SEC Filing  
9/6/2016Paul J MitchellDirectorSell2,000$45.92$91,840.00View SEC Filing  
8/4/2016Paul J MitchellDirectorSell2,000$49.48$98,960.00View SEC Filing  
7/27/2016Elliot EhrichCMOSell35,199$51.95$1,828,588.05View SEC Filing  
7/5/2016Paul J MitchellDirectorSell2,000$45.81$91,620.00View SEC Filing  
6/6/2016Paul J MitchellDirectorSell2,000$44.98$89,960.00View SEC Filing  
5/4/2016Paul J MitchellDirectorSell2,000$38.60$77,200.00View SEC Filing  
4/20/2016Michael J LandineSVPSell16,875$41.09$693,393.75View SEC Filing  
4/19/2016Richard F PopsCEOSell18,750$40.15$752,812.50View SEC Filing  
4/18/2016Iain Michael BrownCAOSell5,368$39.27$210,801.36View SEC Filing  
4/13/2016Elliot EhrichCMOSell11,698$37.66$440,546.68View SEC Filing  
4/12/2016Richard F PopsCEOSell25,000$37.79$944,750.00View SEC Filing  
4/4/2016Paul J MitchellDirectorSell2,000$35.65$71,300.00View SEC Filing  
3/22/2016Richard F PopsCEOSell25,000$31.77$794,250.00View SEC Filing  
3/15/2016Richard F PopsCEOSell25,000$31.40$785,000.00View SEC Filing  
3/4/2016Paul J MitchellDirectorSell2,000$32.80$65,600.00View SEC Filing  
3/3/2016David W AnsticeDirectorBuy5,000$32.87$164,350.00View SEC Filing  
2/4/2016Paul J. MitchellDirectorSell2,000$32.81$65,620.00View SEC Filing  
1/4/2016Robert A BreyerDirectorSell2,000$77.33$154,660.00View SEC Filing  
12/28/2015Mark StejbachinsiderSell10,000$80.24$802,400.00View SEC Filing  
12/23/2015Shane CookeinsiderSell18,000$77.23$1,390,140.00View SEC Filing  
12/7/2015Michael J. LandineSVPSell3,750$73.02$273,825.00View SEC Filing  
12/7/2015Richard F. PopsCEOSell37,500$72.06$2,702,250.00View SEC Filing  
12/1/2015Mark StejbachinsiderSell18,000$72.18$1,299,240.00View SEC Filing  
12/1/2015Michael J. LandineSVPSell10,000$72.18$721,800.00View SEC Filing  
12/1/2015Richard F. PopsCEOSell50,000$72.29$3,614,500.00View SEC Filing  
12/1/2015Robert A BreyerDirectorSell2,000$73.46$146,920.00View SEC Filing  
11/23/2015Shane CookeinsiderSell18,000$72.62$1,307,160.00View SEC Filing  
11/2/2015Mark StejbachinsiderSell18,000$72.06$1,297,080.00View SEC Filing  
11/2/2015Robert A BreyerDirectorSell2,000$71.80$143,600.00View SEC Filing  
10/29/2015Iain Michael BrownCAOSell10,822$69.99$757,431.78View SEC Filing  
10/23/2015Shane CookeinsiderSell18,000$62.03$1,116,540.00View SEC Filing  
10/13/2015James M. FratesCFOSell20,000$59.78$1,195,600.00View SEC Filing  
10/2/2015Robert A. BreyerDirectorSell2,000$60.00$120,000.00View SEC Filing  
9/23/2015Shane CookeinsiderSell18,000$67.09$1,207,620.00View SEC Filing  
9/17/2015Michael J. LandineSVPSell10,000$71.20$712,000.00View SEC Filing  
9/17/2015Richard F. PopsCEOSell50,000$71.27$3,563,500.00View SEC Filing  
9/15/2015James M. FratesCFOSell20,000$71.10$1,422,000.00View SEC Filing  
9/10/2015Michael J. LandineSVPSell10,000$67.61$676,100.00View SEC Filing  
9/10/2015Richard F. PopsCEOSell50,000$67.57$3,378,500.00View SEC Filing  
9/1/2015Robert A BreyerDirectorSell2,000$61.43$122,860.00View SEC Filing  
8/24/2015Shane CookeinsiderSell18,000$57.65$1,037,700.00View SEC Filing  
7/23/2015Shane CookeInsiderSell18,000$69.79$1,256,220.00View SEC Filing  
7/20/2015Gordon G PughCOOSell18,750$70.10$1,314,375.00View SEC Filing  
7/14/2015James M FratesCFOSell20,000$65.79$1,315,800.00View SEC Filing  
7/1/2015Gordon G PughCOOSell13,750$65.13$895,537.50View SEC Filing  
7/1/2015Robert A BreyerDirectorSell2,000$64.90$129,800.00View SEC Filing  
6/23/2015Shane CookeInsiderSell18,000$66.84$1,203,120.00View SEC Filing  
6/17/2015Paul J MitchellDirectorSell15,500$65.10$1,009,050.00View SEC Filing  
6/16/2015Gordon G PughCOOSell32,977$63.11$2,081,178.47View SEC Filing  
6/16/2015James M FratesCFOSell10,000$58.63$586,300.00View SEC Filing  
6/1/2015Paul J MitchellDirectorSell1,500$60.78$91,170.00View SEC Filing  
6/1/2015Rebecca PetersonSVPSell21,983$60.05$1,320,079.15View SEC Filing  
5/26/2015Rebecca PetersonSVPSell1,322$60.49$79,967.78View SEC Filing  
5/26/2015Shane CookeInsiderSell18,000$60.31$1,085,580.00View SEC Filing  
5/22/2015Rebecca PetersonSVPSell28,558$61.71$1,762,314.18View SEC Filing  
5/12/2015James M FratesCFOSell10,000$59.34$593,400.00View SEC Filing  
5/4/2015Robert A BreyerDirectorSell2,000$60.00$120,000.00View SEC Filing  
5/1/2015Paul J MitchellDirectorSell1,500$55.79$83,685.00View SEC Filing  
4/23/2015Shane CookeInsiderSell18,000$62.55$1,125,900.00View SEC Filing  
4/21/2015Elliot EhrichCMOSell25,000$62.39$1,559,750.00View SEC Filing  
4/15/2015Gordon G PughCOOSell13,750$63.21$869,137.50View SEC Filing  
4/15/2015James M FratesCFOSell10,000$62.42$624,200.00View SEC Filing  
4/15/2015Paul J MitchellDirectorSell1,500$62.71$94,065.00View SEC Filing  
4/1/2015Robert A BreyerDirectorSell5,000$61.22$306,100.00View SEC Filing  
3/23/2015Shane CookeInsiderSell18,000$65.33$1,175,940.00View SEC Filing  
3/16/2015Elliot EhrichCMOSell18,000$66.81$1,202,580.00View SEC Filing  
3/10/2015James M FratesCFOSell10,000$66.25$662,500.00View SEC Filing  
3/5/2015Rebecca PetersonSVPSell17,737$71.37$1,265,889.69View SEC Filing  
3/2/2015Gordon G PughCOOSell15,000$71.39$1,070,850.00View SEC Filing  
3/2/2015Robert A BreyerDirectorSell5,000$70.86$354,300.00View SEC Filing  
2/23/2015Shane CookeInsiderSell18,000$74.29$1,337,220.00View SEC Filing  
2/17/2015Elliot EhrichCMOSell18,000$70.87$1,275,660.00View SEC Filing  
2/3/2015James M FratesCFOSell10,000$70.83$708,300.00View SEC Filing  
2/2/2015Gordon G PughCOOSell15,000$72.01$1,080,150.00View SEC Filing  
2/2/2015Robert A BreyerDirectorSell5,000$72.91$364,550.00View SEC Filing  
1/26/2015Gordon G PughCOOSell15,000$70.02$1,050,300.00View SEC Filing  
1/23/2015Shane CookeInsiderSell118,000$69.13$8,157,340.00View SEC Filing  
1/16/2015Floyd E BloomDirectorSell20,000$67.12$1,342,400.00View SEC Filing  
1/15/2015Elliot EhrichCMOSell18,375$66.45$1,221,018.75View SEC Filing  
1/15/2015James M FratesCFOSell10,000$66.86$668,600.00View SEC Filing  
1/7/2015Kathryn L BibersteinSVPSell28,374$65.00$1,844,310.00View SEC Filing  
1/2/2015Robert A BreyerDirectorSell5,000$58.57$292,850.00View SEC Filing  
12/11/2014Richard F PopsCEOSell100,000$56.04$5,604,000.00View SEC Filing  
12/10/2014James M FratesCFOSell18,870$56.07$1,058,040.90View SEC Filing  
12/9/2014Michael J LandineSVPSell18,000$56.82$1,022,760.00View SEC Filing  
12/5/2014Kathryn L BibersteinSVPSell15,433$57.61$889,095.13View SEC Filing  
12/1/2014Robert A BreyerDirectorSell5,000$54.64$273,200.00View SEC Filing  
11/19/2014James M FratesCFOSell8,000$53.86$430,880.00View SEC Filing  
11/13/2014Richard F PopsCEOSell100,000$52.87$5,287,000.00View SEC Filing  
11/7/2014James M FratesCFOSell13,303$49.98$664,883.94View SEC Filing  
11/6/2014Kathryn L BibersteinSVPSell20,000$50.54$1,010,800.00View SEC Filing  
11/3/2014Robert A BreyerDirectorSell5,000$50.05$250,250.00View SEC Filing  
10/23/2014Gordon G PughCOOSell14,577$45.00$655,965.00View SEC Filing  
10/8/2014James M FratesCFOSell16,000$41.00$656,000.00View SEC Filing  
10/1/2014Robert A BreyerDirectorSell5,000$42.59$212,950.00View SEC Filing  
9/24/2014James M FratesCFOSell16,000$45.29$724,640.00View SEC Filing  
9/18/2014Michael J LandineSVPSell15,000$45.60$684,000.00View SEC Filing  
9/17/2014Gordon G PughCOOSell14,900$45.04$671,096.00View SEC Filing  
9/17/2014Richard F PopsCEOSell50,000$44.89$2,244,500.00View SEC Filing  
9/10/2014James M FratesCFOSell16,000$43.18$690,880.00View SEC Filing  
9/2/2014Gordon G PughCOOSell1,100$45.08$49,588.00View SEC Filing  
9/2/2014Robert A BreyerDirectorSell5,000$45.12$225,600.00View SEC Filing  
8/27/2014James M FratesCFOSell16,000$45.08$721,280.00View SEC Filing  
8/26/2014Gordon G PughCOOSell16,000$45.00$720,000.00View SEC Filing  
8/13/2014James M FratesCFOSell15,000$41.37$620,550.00View SEC Filing  
8/11/2014Elliot EhrichCMOSell16,667$41.65$694,180.55View SEC Filing  
8/4/2014Gordon G PughCOOSell23,250$43.20$1,004,400.00View SEC Filing  
8/1/2014Robert A BreyerDirectorSell5,000$42.53$212,650.00View SEC Filing  
7/16/2014James M FratesCFOSell8,000$46.50$372,000.00View SEC Filing  
7/9/2014Elliot EhrichCMOSell16,667$47.41$790,182.47View SEC Filing  
7/9/2014James M FratesCFOSell7,000$47.41$331,870.00View SEC Filing  
7/3/2014Michael J LandineSVPSell7,000$51.31$359,170.00View SEC Filing  
7/2/2014Richard F PopsCEOSell50,000$51.69$2,584,500.00View SEC Filing  
7/1/2014Gordon G PughCOOSell16,000$46.49$743,840.00View SEC Filing  
7/1/2014Robert A BreyerDirectorSell5,000$50.57$252,850.00View SEC Filing  
6/26/2014Michael J LandineSVPSell10,000$49.92$499,200.00View SEC Filing  
6/25/2014James M FratesCFOSell7,000$50.22$351,540.00View SEC Filing  
6/25/2014Richard F PopsCEOSell50,000$49.87$2,493,500.00View SEC Filing  
6/20/2014Paul J MitchellDirectorSell17,000$50.00$850,000.00View SEC Filing  
6/19/2014Elliot EhrichCMOSell17,282$47.10$813,982.20View SEC Filing  
6/19/2014Michael J LandineSVPSell10,000$47.01$470,100.00View SEC Filing  
6/18/2014Richard F PopsCEOSell50,000$46.72$2,336,000.00View SEC Filing  
6/17/2014Kathryn L BibersteinSVPSell8,400$47.41$398,244.00View SEC Filing  
6/11/2014James M FratesCFOSell7,000$47.72$334,040.00View SEC Filing  
6/9/2014Elliot EhrichCMOSell16,667$48.15$802,516.05View SEC Filing  
6/2/2014Gordon G PughCOOSell16,000$45.34$725,440.00View SEC Filing  
6/2/2014Robert A BreyerDirectorSell5,000$45.18$225,900.00View SEC Filing  
5/30/2014Rebecca PetersonSVPSell21,981$45.86$1,008,048.66View SEC Filing  
5/23/2014Rebecca PetersonSVPSell1,321$45.08$59,550.68View SEC Filing  
5/22/2014Elliot EhrichCMOSell2,378$44.49$105,797.22View SEC Filing  
5/22/2014Gordon PughCOOSell15,700$45.25$710,425.00View SEC Filing  
5/22/2014Rebecca PetersonSVPSell19,807$44.02$871,904.14View SEC Filing  
5/21/2014Elliot EhrichCMOSell1,981$44.00$87,164.00View SEC Filing  
5/21/2014James FratesCFOSell7,000$44.30$310,100.00View SEC Filing  
5/20/2014Rebecca PetersonSVPSell20,307$44.05$894,523.35View SEC Filing  
5/19/2014Elliot EhrichCMOSell2,206$43.55$96,071.30View SEC Filing  
5/8/2014Floyd BloomDirectorSell10,000$46.16$461,600.00View SEC Filing  
5/5/2014Robert BreyerDirectorSell5,000$46.72$233,600.00View SEC Filing  
5/1/2014Paul MitchellDirectorSell1,000$45.90$45,900.00View SEC Filing  
4/9/2014James FratesCFOSell7,000$42.91$300,370.00View SEC Filing  
4/1/2014Paul MitchellDirectorSell1,500$44.14$66,210.00View SEC Filing  
3/19/2014James FratesCFOSell7,000$46.84$327,880.00View SEC Filing  
3/11/2014Wendy DixonDirectorBuy1,600$47.37$75,792.00View SEC Filing  
3/5/2014James FratesCFOSell7,000$47.78$334,460.00View SEC Filing  
2/18/2014Elliot EhrichCMOSell7,718$52.45$404,809.10View SEC Filing  
2/3/2014Paul MitchellDirectorSell1,500$48.15$72,225.00View SEC Filing  
1/21/2014Elliot EhrichCMOSell7,718$48.61$375,171.98View SEC Filing  
1/16/2014Elliot EhrichCMOSell14,555$47.35$689,179.25View SEC Filing  
1/16/2014Gordon PughCOOSell30,000$47.16$1,414,800.00View SEC Filing  
1/16/2014James FratesCFOSell7,000$47.40$331,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Alkermes PLC (NASDAQ ALKS)

Source:
DateHeadline
Alkermes Named a Top Place to Work by The Boston GlobeAlkermes Named a Top Place to Work by The Boston Globe
finance.yahoo.com - November 20 at 5:11 PM
Alkermes PLC (ALKS) Receives Average Rating of "Hold" from BrokeragesAlkermes PLC (ALKS) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 20 at 9:00 AM
Alkermes: Bearish Technicals But Several Value Drivers In 2018 - Seeking AlphaAlkermes: Bearish Technicals But Several Value Drivers In 2018 - Seeking Alpha
seekingalpha.com - November 17 at 3:26 PM
Why Biotech Sage Therapeutics Is OvervaluedWhy Biotech Sage Therapeutics Is Overvalued
finance.yahoo.com - November 17 at 3:26 PM
Alkermes New Drug Application For Investigational Product Designed For Initiation Onto ARISTADA® Accepted For Filing By U.S. FDAAlkermes' New Drug Application For Investigational Product Designed For Initiation Onto ARISTADA® Accepted For Filing By U.S. FDA
www.thestreet.com - November 17 at 10:52 AM
Lifshitz & Miller LLP Announces Investigation of Acorda Therapeutics, Inc., Alkermes plc, ASB Financial Corp., CalAtlantic Group, Capella Education Company, INC Research Holdings, Inc. and YuMe, Inc.Lifshitz & Miller LLP Announces Investigation of Acorda Therapeutics, Inc., Alkermes plc, ASB Financial Corp., CalAtlantic Group, Capella Education Company, INC Research Holdings, Inc. and YuMe, Inc.
finance.yahoo.com - November 16 at 8:59 PM
Alkermes Says FDA Accepts NDA Filing On ARISTADAAlkermes Says FDA Accepts NDA Filing On ARISTADA
www.nasdaq.com - November 16 at 11:00 AM
FDA accepts Alkermes marketing application for schizophrenia therapy initiation treatmentFDA accepts Alkermes' marketing application for schizophrenia therapy initiation treatment
seekingalpha.com - November 16 at 11:00 AM
Biotech Alkermes Could Jump On Opioid Treatment SalesBiotech Alkermes Could Jump On Opioid Treatment Sales
finance.yahoo.com - November 16 at 11:00 AM
Alkermes’ New Drug Application for Investigational Product Designed for Initiation Onto ARISTADA® Accepted for Filing by U.S. FDAAlkermes’ New Drug Application for Investigational Product Designed for Initiation Onto ARISTADA® Accepted for Filing by U.S. FDA
finance.yahoo.com - November 16 at 11:00 AM
VIVITROL® and Value of Medication-Assisted Treatment for Opioid Dependence Featured in Study Sponsored by National Institute on Drug AbuseVIVITROL® and Value of Medication-Assisted Treatment for Opioid Dependence Featured in Study Sponsored by National Institute on Drug Abuse
finance.yahoo.com - November 14 at 9:14 PM
$239.12 Million in Sales Expected for Alkermes PLC (ALKS) This Quarter$239.12 Million in Sales Expected for Alkermes PLC (ALKS) This Quarter
www.americanbankingnews.com - November 12 at 1:50 AM
ACT NOW: Monteverde & Associates PC Announces an Investigation of Alkermes plc. - ALKS - PR Newswire (press release)ACT NOW: Monteverde & Associates PC Announces an Investigation of Alkermes plc. - ALKS - PR Newswire (press release)
www.prnewswire.com - November 11 at 8:34 PM
ACT NOW: Monteverde & Associates PC Announces an Investigation of Alkermes plc. - ALKSACT NOW: Monteverde & Associates PC Announces an Investigation of Alkermes plc. - ALKS
finance.yahoo.com - November 11 at 3:33 PM
Alkermes plc (ALKS) Reports Positive Preclinical Data for ALKS 4230 Presented at SITC - StreetInsider.comAlkermes plc (ALKS) Reports Positive Preclinical Data for ALKS 4230 Presented at SITC - StreetInsider.com
www.streetinsider.com - November 10 at 7:30 PM
Alkermes PLC (ALKS) SVP Sells $995,944.56 in StockAlkermes PLC (ALKS) SVP Sells $995,944.56 in Stock
www.americanbankingnews.com - November 9 at 7:02 PM
Alkermes Reveals Recipients of the 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use DisordersAlkermes Reveals Recipients of the 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders
finance.yahoo.com - November 9 at 4:49 PM
Alkermes Calls for Impartial National Review of Scientific Data Supporting the Use of FDA-Approved Treatment Options for Opioid DependenceAlkermes Calls for Impartial National Review of Scientific Data Supporting the Use of FDA-Approved Treatment Options for Opioid Dependence
finance.yahoo.com - November 9 at 4:49 PM
Alkermes plc (ALKS) Reports Positive Preclinical Data for ALKS 4230 Presented at SITCAlkermes plc (ALKS) Reports Positive Preclinical Data for ALKS 4230 Presented at SITC
www.streetinsider.com - November 8 at 5:59 PM
Positive Preclinical Data for ALKS 4230 Presented at Society for Immunotherapy of Cancer (SITC) 32nd Annual MeetingPositive Preclinical Data for ALKS 4230 Presented at Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
finance.yahoo.com - November 8 at 5:59 PM
Alkermes’ Corporate Presentation to be Webcast at the Jefferies 2017 London Healthcare ConferenceAlkermes’ Corporate Presentation to be Webcast at the Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 8 at 5:59 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alkermes plc - ALKS - PR Newswire (press release)SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alkermes plc - ALKS - PR Newswire (press release)
www.prnewswire.com - November 7 at 5:24 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alkermes plc (ALKS) - PR Newswire (press release)SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alkermes plc (ALKS) - PR Newswire (press release)
www.prnewswire.com - November 7 at 5:24 PM
Kamala Harris investigates opioid addiction drugKamala Harris investigates opioid addiction drug
finance.yahoo.com - November 7 at 5:24 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alkermes plc - ALKSSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alkermes plc - ALKS
finance.yahoo.com - November 7 at 5:24 PM
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Alkermes plc – ALKSEQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Alkermes plc – ALKS
finance.yahoo.com - November 7 at 5:24 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alkermes plc (ALKS)SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alkermes plc (ALKS)
finance.yahoo.com - November 7 at 5:24 PM
U.S. senator investigating Waltham’s Alkermes over opioid addiction drugU.S. senator investigating Waltham’s Alkermes over opioid addiction drug
finance.yahoo.com - November 6 at 4:31 PM
Alkermes PLC (ALKS) Director Richard F. Pops Sells 50,000 SharesAlkermes PLC (ALKS) Director Richard F. Pops Sells 50,000 Shares
www.americanbankingnews.com - November 3 at 8:35 PM
Alkermes PLC (ALKS) SVP Michael J. Landine Sells 15,000 SharesAlkermes PLC (ALKS) SVP Michael J. Landine Sells 15,000 Shares
www.americanbankingnews.com - November 3 at 5:26 PM
Alkermes Plc :ALKS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017Alkermes Plc :ALKS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017
finance.yahoo.com - November 1 at 4:14 PM
ETFs with exposure to Alkermes Plc : October 31, 2017ETFs with exposure to Alkermes Plc : October 31, 2017
finance.yahoo.com - October 31 at 4:56 PM
Alkermes’ Corporate Presentation to be Webcast at the Credit Suisse 26th Annual Healthcare ConferenceAlkermes’ Corporate Presentation to be Webcast at the Credit Suisse 26th Annual Healthcare Conference
finance.yahoo.com - October 31 at 4:56 PM
Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : October 30, 2017Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : October 30, 2017
finance.yahoo.com - October 30 at 4:35 PM
Edited Transcript of ALKS earnings conference call or presentation 26-Oct-17 12:30pm GMTEdited Transcript of ALKS earnings conference call or presentation 26-Oct-17 12:30pm GMT
finance.yahoo.com - October 29 at 3:35 PM
Alkermes plc (ALKS) Presents Data Demonstrating Safety and Gastrointestinal Tolerability Profile of ALKS 8700 for ... - StreetInsider.comAlkermes plc (ALKS) Presents Data Demonstrating Safety and Gastrointestinal Tolerability Profile of ALKS 8700 for ... - StreetInsider.com
www.streetinsider.com - October 28 at 4:11 PM
Credit Suisse Group Cuts Alkermes PLC (ALKS) Price Target to $66.00Credit Suisse Group Cuts Alkermes PLC (ALKS) Price Target to $66.00
www.americanbankingnews.com - October 28 at 3:34 PM
J P Morgan Chase & Co Reiterates $78.00 Price Target for Alkermes PLC (ALKS)J P Morgan Chase & Co Reiterates $78.00 Price Target for Alkermes PLC (ALKS)
www.americanbankingnews.com - October 28 at 11:10 AM
Alkermes PLC (ALKS) Given New $54.00 Price Target at UBS AGAlkermes PLC (ALKS) Given New $54.00 Price Target at UBS AG
www.americanbankingnews.com - October 27 at 7:36 PM
Alkermes plc (ALKS) Presents Data Demonstrating Safety and Gastrointestinal Tolerability Profile of ALKS 8700 for Treatment of MSAlkermes plc (ALKS) Presents Data Demonstrating Safety and Gastrointestinal Tolerability Profile of ALKS 8700 for Treatment of MS
www.streetinsider.com - October 27 at 5:50 PM
Alkermes (ALKS) in Focus: Stock Moves 11.1% HigherAlkermes (ALKS) in Focus: Stock Moves 11.1% Higher
finance.yahoo.com - October 27 at 5:50 PM
Alkermes Presents Data Demonstrating Safety and Gastrointestinal Tolerability Profile of ALKS 8700 for the Treatment of Multiple SclerosisAlkermes Presents Data Demonstrating Safety and Gastrointestinal Tolerability Profile of ALKS 8700 for the Treatment of Multiple Sclerosis
finance.yahoo.com - October 27 at 5:50 PM
The Clear Reason Alkermes Plc's Shares Jumped by as Much as 12%The Clear Reason Alkermes Plc's Shares Jumped by as Much as 12%
finance.yahoo.com - October 26 at 8:47 PM
Alkermes PLC (ALKS) Given a $62.00 Price Target by Citigroup Inc AnalystsAlkermes PLC (ALKS) Given a $62.00 Price Target by Citigroup Inc Analysts
www.americanbankingnews.com - October 26 at 6:34 PM
Barclays PLC Reiterates $50.00 Price Target for Alkermes PLC (ALKS)Barclays PLC Reiterates $50.00 Price Target for Alkermes PLC (ALKS)
www.americanbankingnews.com - October 26 at 6:34 PM
Alkermes plc Reports Third Quarter 2017 Financial Results - Business Wire (press release)Alkermes plc Reports Third Quarter 2017 Financial Results - Business Wire (press release)
www.businesswire.com - October 26 at 3:46 PM
Alkermes claws back from selloff, up 4% - Seeking AlphaAlkermes claws back from selloff, up 4% - Seeking Alpha
seekingalpha.com - October 26 at 3:46 PM
Alkermes plc (ALKS) Launches Investigational Product Designed for Initiation Onto ARISTADA for Treatment of ... - StreetInsider.comAlkermes plc (ALKS) Launches Investigational Product Designed for Initiation Onto ARISTADA for Treatment of ... - StreetInsider.com
www.streetinsider.com - October 26 at 3:46 PM
Alkermes plc (ALKS): Financial Strength AnalysisAlkermes plc (ALKS): Financial Strength Analysis
finance.yahoo.com - October 26 at 3:46 PM
Alkermes Reports Mixed Results, Updates GuidanceAlkermes Reports Mixed Results, Updates Guidance
finance.yahoo.com - October 26 at 3:46 PM

Social Media

Financials

Chart

Alkermes PLC (NASDAQ ALKS) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.